These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25079671)

  • 1. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
    Hariya N; Mochizuki K; Inoue S; Saito M; Fuchigami M; Goda T; Osonoi T
    Drugs R D; 2014 Sep; 14(3):177-84. PubMed ID: 25079671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
    Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
    Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
    Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
    Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
    Hedrington MS; Davis SN
    Expert Opin Pharmacother; 2019 Dec; 20(18):2229-2235. PubMed ID: 31593486
    [No Abstract]   [Full Text] [Related]  

  • 5. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
    Dash RP; Babu RJ; Srinivas NR
    Xenobiotica; 2018 Jan; 48(1):89-108. PubMed ID: 28010166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
    Kato H; Ohta A; Kobayashi S; Ishii S; Sada Y; Kobayashi H; Ohmori S; Kondo A; Katabami T; Fuse J; Fukuda H; Nagai Y; Tanaka Y
    Endocr J; 2012; 59(4):345-52. PubMed ID: 22301938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
    Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
    Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
    Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
    Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
    Narita T; Yokoyama H; Yamashita R; Sato T; Hosoba M; Morii T; Fujita H; Tsukiyama K; Yamada Y
    Diabetes Obes Metab; 2012 Mar; 14(3):283-7. PubMed ID: 22051162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
    Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
    Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
    Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
    Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
    Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
    Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study.
    Shimabukuro M; Tanaka A; Sata M; Dai K; Shibata Y; Inoue Y; Ikenaga H; Kishimoto S; Ogasawara K; Takashima A; Niki T; Arasaki O; Oshiro K; Mori Y; Ishihara M; Node K;
    Cardiovasc Diabetol; 2017 Jul; 16(1):86. PubMed ID: 28683829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
    Osonoi T; Saito M; Tamasawa A; Ishida H; Osonoi Y
    Expert Opin Pharmacother; 2014 Jul; 15(10):1325-35. PubMed ID: 24866329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
    Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
    Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
    Scheen AJ
    Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.